Assetmark Inc. Increases Stake in Abbott Laboratories $ABT

Assetmark Inc. grew its holdings in Abbott Laboratories (NYSE:ABT) by 8.9% during the 1st quarter, Holdings Channel reports. The fund owned 202,552 shares of the healthcare product maker’s stock after buying an additional 16,506 shares during the period. Assetmark Inc.’s holdings in Abbott Laboratories were worth $20,796,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. NovaPoint Capital LLC boosted its position in shares of Abbott Laboratories by 7.0% in the first quarter. NovaPoint Capital LLC now owns 41,167 shares of the healthcare product maker’s stock worth $4,227,000 after purchasing an additional 2,694 shares during the period. Financiere des Professionnels Fonds d investissement inc. bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at $2,185,000. Bessemer Group Inc. lifted its stake in shares of Abbott Laboratories by 1.6% during the 1st quarter. Bessemer Group Inc. now owns 1,013,900 shares of the healthcare product maker’s stock valued at $104,098,000 after buying an additional 16,135 shares in the last quarter. Gerald Baker Financial Group LLC bought a new position in Abbott Laboratories in the 1st quarter worth $922,000. Finally, Allspring Global Investments Holdings LLC increased its stake in Abbott Laboratories by 11.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 468,676 shares of the healthcare product maker’s stock worth $47,983,000 after buying an additional 50,017 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on ABT. Stifel Nicolaus decreased their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. JPMorgan Chase & Co. increased their target price on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday. Sanford C. Bernstein decreased their target price on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, July 7th. Finally, Barclays cut their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a report on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $118.61.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $100.71 on Friday. The company has a market cap of $175.41 billion, a price-to-earnings ratio of 32.59, a PEG ratio of 1.73 and a beta of 0.61. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The stock’s 50 day simple moving average is $89.89 and its two-hundred day simple moving average is $102.17. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The firm had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the prior year, the company earned $1.26 EPS. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Insiders Place Their Bets

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.